Monday, August 16, 1993
DNX finds allure in service business
If DNX Corp. (DNXX) doesn't find a partner for its core blood substitute program, it
may transform itself into a different company focused on its preclinical services
division, Pharmakon Research International.
Paul Schmitt, president and CEO, told BioCentury that the company's blood substitute
business is responsible for a "large portion" of DNXX's $1 million per month
burn rate. DNXX is developing recombinant human hemoglobin produced in transgenic